Cargando…

Risk-Based Prenatal Hepatitis C Testing Practices and Results, Alaska 2013-2016

Hepatitis C virus (HCV) infection in pregnant women is of concern as it presents a health threat not only to the mother, but also to her infant. A retrospective analysis was performed to evaluate HCV testing and exposure in women who delivered infants between 2013 and 2016 at a referral hospital in...

Descripción completa

Detalles Bibliográficos
Autores principales: Nolen, Leisha D., Gustin, Courtney, Seeman, Sara, Murphy, Neil, Truitt, Sarah, Schillie, Sarah, Bruce, Michael G., Bruden, Dana, Tiesinga, James, McMahon, Brian
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Hindawi 2019
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6582887/
https://www.ncbi.nlm.nih.gov/pubmed/31275902
http://dx.doi.org/10.1155/2019/8654741
_version_ 1783428419337322496
author Nolen, Leisha D.
Gustin, Courtney
Seeman, Sara
Murphy, Neil
Truitt, Sarah
Schillie, Sarah
Bruce, Michael G.
Bruden, Dana
Tiesinga, James
McMahon, Brian
author_facet Nolen, Leisha D.
Gustin, Courtney
Seeman, Sara
Murphy, Neil
Truitt, Sarah
Schillie, Sarah
Bruce, Michael G.
Bruden, Dana
Tiesinga, James
McMahon, Brian
author_sort Nolen, Leisha D.
collection PubMed
description Hepatitis C virus (HCV) infection in pregnant women is of concern as it presents a health threat not only to the mother, but also to her infant. A retrospective analysis was performed to evaluate HCV testing and exposure in women who delivered infants between 2013 and 2016 at a referral hospital in Alaska. Multiple risk behaviors were evaluated, including drug dependency or abuse (drug abuse), tobacco use, alcohol dependency or abuse, and late presentation to prenatal care. Of the 2856 women who delivered between 2013 and 2016, 470 (16.5%) were tested for HCV during pregnancy and 1356 (47.5%) were tested at any time prior to delivery (including pregnancy); 62 (2.2%) were positive for HCV antibodies. Of the 162 women with a documented history of drug abuse, 95 (58.6%) were tested for HCV during pregnancy and 143 (88.3%) were tested at any time prior to delivery (including pregnancy); 30 (18.5%) were positive for HCV antibodies. Forty-nine women (34%) with a documented history of drug abuse who were not previously known to be HCV positive were not tested for HCV during their pregnancy. In conclusion, approximately 2% of pregnant women in the study population were known to have been exposed to HCV by the time of their delivery. One-third of women with documented drug abuse did not have an HCV test during pregnancy, revealing gaps in HCV testing of pregnant women. Further studies are needed to understand the full costs and benefits of risk-based screening versus universal screening in this and other populations.
format Online
Article
Text
id pubmed-6582887
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher Hindawi
record_format MEDLINE/PubMed
spelling pubmed-65828872019-07-04 Risk-Based Prenatal Hepatitis C Testing Practices and Results, Alaska 2013-2016 Nolen, Leisha D. Gustin, Courtney Seeman, Sara Murphy, Neil Truitt, Sarah Schillie, Sarah Bruce, Michael G. Bruden, Dana Tiesinga, James McMahon, Brian Can J Gastroenterol Hepatol Research Article Hepatitis C virus (HCV) infection in pregnant women is of concern as it presents a health threat not only to the mother, but also to her infant. A retrospective analysis was performed to evaluate HCV testing and exposure in women who delivered infants between 2013 and 2016 at a referral hospital in Alaska. Multiple risk behaviors were evaluated, including drug dependency or abuse (drug abuse), tobacco use, alcohol dependency or abuse, and late presentation to prenatal care. Of the 2856 women who delivered between 2013 and 2016, 470 (16.5%) were tested for HCV during pregnancy and 1356 (47.5%) were tested at any time prior to delivery (including pregnancy); 62 (2.2%) were positive for HCV antibodies. Of the 162 women with a documented history of drug abuse, 95 (58.6%) were tested for HCV during pregnancy and 143 (88.3%) were tested at any time prior to delivery (including pregnancy); 30 (18.5%) were positive for HCV antibodies. Forty-nine women (34%) with a documented history of drug abuse who were not previously known to be HCV positive were not tested for HCV during their pregnancy. In conclusion, approximately 2% of pregnant women in the study population were known to have been exposed to HCV by the time of their delivery. One-third of women with documented drug abuse did not have an HCV test during pregnancy, revealing gaps in HCV testing of pregnant women. Further studies are needed to understand the full costs and benefits of risk-based screening versus universal screening in this and other populations. Hindawi 2019-06-02 /pmc/articles/PMC6582887/ /pubmed/31275902 http://dx.doi.org/10.1155/2019/8654741 Text en Copyright © 2019 Leisha D. Nolen et al. https://creativecommons.org/licenses/by/4.0/ This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Research Article
Nolen, Leisha D.
Gustin, Courtney
Seeman, Sara
Murphy, Neil
Truitt, Sarah
Schillie, Sarah
Bruce, Michael G.
Bruden, Dana
Tiesinga, James
McMahon, Brian
Risk-Based Prenatal Hepatitis C Testing Practices and Results, Alaska 2013-2016
title Risk-Based Prenatal Hepatitis C Testing Practices and Results, Alaska 2013-2016
title_full Risk-Based Prenatal Hepatitis C Testing Practices and Results, Alaska 2013-2016
title_fullStr Risk-Based Prenatal Hepatitis C Testing Practices and Results, Alaska 2013-2016
title_full_unstemmed Risk-Based Prenatal Hepatitis C Testing Practices and Results, Alaska 2013-2016
title_short Risk-Based Prenatal Hepatitis C Testing Practices and Results, Alaska 2013-2016
title_sort risk-based prenatal hepatitis c testing practices and results, alaska 2013-2016
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6582887/
https://www.ncbi.nlm.nih.gov/pubmed/31275902
http://dx.doi.org/10.1155/2019/8654741
work_keys_str_mv AT nolenleishad riskbasedprenatalhepatitisctestingpracticesandresultsalaska20132016
AT gustincourtney riskbasedprenatalhepatitisctestingpracticesandresultsalaska20132016
AT seemansara riskbasedprenatalhepatitisctestingpracticesandresultsalaska20132016
AT murphyneil riskbasedprenatalhepatitisctestingpracticesandresultsalaska20132016
AT truittsarah riskbasedprenatalhepatitisctestingpracticesandresultsalaska20132016
AT schilliesarah riskbasedprenatalhepatitisctestingpracticesandresultsalaska20132016
AT brucemichaelg riskbasedprenatalhepatitisctestingpracticesandresultsalaska20132016
AT brudendana riskbasedprenatalhepatitisctestingpracticesandresultsalaska20132016
AT tiesingajames riskbasedprenatalhepatitisctestingpracticesandresultsalaska20132016
AT mcmahonbrian riskbasedprenatalhepatitisctestingpracticesandresultsalaska20132016